Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma
Cytochrome b5 reductase 2 (CYB5R2), a member of the flavoprotein pyridine nucleotide cytochrome reductase family, is associated with a number of physiological reactions. However, its role in cancer, especially nasopharyngeal carcinoma (NPC), has not been addressed. Here, we investigate the transcript levels and promoter methylation status of CYB5R2 in NPC derived cell lines and tumor biopsies and experimentally address its role as a tumor suppressor gene. We find that CYB5R2 transcript levels are decreased in NPC cell lines and tumor biopsies. Promoter hypermethylation of CYB5R2 was detected in all six tested NPC cell lines and in 84 % of primary NPC tumor biopsies but not in normal nasopharyngeal epithelium. Clinically, CYB5R2 methylation was associated with lymph node metastasis in NPC patients (P < 0.05). The endogenous expression of CYB5R2 could be restored in vitro by the methyltransferase inhibitor 5-aza-2′-deoxycytidine in NPC cell lines. Ectopic expression of CYB5R2 had an inhibitory effect on proliferation, clonogenicity and migration of NPC cells. Moreover, in vivo tests in nude mice indicated that ectopic expression of CYB5R2 reduces the tumorigenicity of CYB5R2-negative NPC cells. Collectively, these findings suggest that CYB5R2 may be a functional tumor suppressor gene, frequently inactivated by hypermethylation of its promoter in NPC. We report here the first instance of epigenetic downregulation in NPC tumor biopsies of a key enzyme, CYB5R2, which is responsible for the detoxification of environmental carcinogens. We propose the possibility of utilizing CYB5R2 promoter methylation as a diagnostic biomarker of NPC in the future.
Hinweise
G. Huang and X. Zeng contributed equally to this work.
Introduction
Nasopharyngeal cancer (NPC) is one of the most common head and neck malignant tumors in Southern China, with an annual incidence rate of 25–50 per 100,000 person-years, while the frequency in Caucasians in other countries is less than one case per 100,000 person-years [1, 2]. The etiology of NPC is multifactorial. Accumulated epidemiological and etiological evidence indicate that NPC develops as a result of a complex interaction between genetic factors, exposure to chemical carcinogens, and latent Epstein–Barr virus (EBV) infection [3‐6]. Specially, environmental factors such as consumption of salt-preserved fish, cigarette smoking and exposure to environmental chemical pollutants have been reported to be of importance in the development of NPC [3, 7, 8]. EBV is strongly associated with NPC, and it has now been found to function as a tumor promoter rather than an initiator in the tumorigenesis of NPC. But the fact that the majority of the human population (>90 %) carry EBV suggest that host genetic factors might also contribute to the carcinogenesis of NPC, making it develop only in a small subset of the exposed population. However, the relative contribution of these factors in the pathogenesis of NPC remains to be elucidated in detail.
Recent studies demonstrate that genes for carcinogen-metabolizing enzymes may play critical roles in determining individual susceptibility to NPC. Genetic or epigenetic alterations that alter the expression or function of these genes, may decrease the efficiency of the corresponding carcinogen detoxification processes, which, in turn, may increase individual susceptibility and cancer risk. Xenobiotics can be detoxified by phase I or II biotransformation enzymes [9], and genetic polymorphisms in genes encoding biotransformation enzymes such as CYP2E1, GSTM1 and GSTT1 were shown to increase individual susceptibility to NPC [10‐13].
Anzeige
Furthermore, growing evidence demonstrates that aberrant epigenetic changes, especially promoter hypermethylation of tumor suppressor genes (TSGs), are important in the multistep carcinogenesis of NPC [14, 15]. However, no studies have looked into the association of epigenetic alterations in xenobiotic-metabolizing enzymes and NPC.
The human CYB5R2 (cytochrome b5 reductase 2), a 276-amino-acid protein, contains one ferredoxin reductase-type flavin adenine dinucleotide-binding domain and belongs to the flavoprotein pyridine nucleotide cytochrome reductase family. It is one of the phase I xenobiotic biotransformation enzymes responsible for detoxification of polycyclic aromatic hydrocarbons and arylhydroxylamine carcinogens, commonly found in cigarette smoke and fried foods [16]. CYB5R2 is involved in various biological processes such as electron transport, oxidation–reduction, lipid metabolism, fatty acid desaturation and/or elongation, cholesterol biosynthesis, drug metabolism, and methemoglobin reduction in erythrocytes [17]. Moreover, it is responsible for reducing both NADH-dependent lucigenin chemiluminescence and 2-[4-iodophenyl]-3-[4-nitrophenyl]-5-[2, 4-disulfophenyl]-2H-tetrazolium monosodium salt in human spermatozoa [17].
In this study, we evaluated the transcriptional levels and methylation status of CYB5R2 in NPC cell lines and primary tumor biopsies. We further addressed the TSG properties of CYB5R2 in NPC by a series of in vitro and in vivo experiments.
Materials and methods
NPC cell lines, primary tumor biopsies and normal nasopharyngeal epithelium (NNE)
Six NPC cell lines (CNE1, CNE2, TW03, C666-1, HNE1, and HONE1) were maintained at 37 °C in the appropriate medium. In total, 70 NPC primary tumor biopsies were collected from newly diagnosed and untreated NPC patients at the department of Otolaryngology—Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University (Nanning, China), with informed consent from the donors. The diagnosis was established by experienced pathologists according to the World Health Organization (WHO) classification for NPC. Twenty-four NNE tissues obtained by tonsillectomy were included as controls. In all, 50 of the 70 NPC biopsies and 12 of the 24 NNEs were processed for DNA extraction, the rest 20 NPC and 12 NNEs were used for RNA extraction. All biopsy samples were stored in liquid nitrogen. Ethical permission for this study was granted by the Ethical Review Committee of First Affiliated Hospital of Guangxi Medical University, China.
Anzeige
Semi-quantitative RT-PCR
Preparation of total RNA, first-strand synthesis of cDNA and RT-PCR was performed as described [18]. All primer sequences, annealing temperatures, cycling conditions and expected PCR product sizes are listed in Table 1. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified from the same cDNA sample as an internal control. The amplified PCR products were visualized after electrophoresis in 2 % agarose gels and semi-quantitative analysis was performed using Quantity One v4.4.0 software (Bio-Rad, USA).
Table 1
Primer sequences, product size and annealing temperature used in this study
Primers
Primer sequences
Product size (bp)
Annealing temperature
RT-PCR
CYB5R2- forward
5′-CCTTGTAGGGACCCGTCCC-3′
291
66 °C
CYB5R2- reverse
5′-GACAGGGGTGTAAGCCCTG-3′
GAPDH-forward
5′-AAGCTCACTGGCATGGCCTT-3′
375
60 °C
GAPDH-reverse
5′-CTCTCTTCCTCTTGTGCTCTTG-3′
Methylation-specific PCR
MSP-forward
5′-GGGGAGCGGGTTAGTCGTC-3′
140
65 °C
MSP-reverse
5′-GAACCCGCAAACTCGTAACGTC-3′
USP-forward
5′-GGGGAGTGGGTTAGTTGTTG-3′
146
58 °C
USP-reverse
5′-CACCACAAACCCACAAACTC-3′
Bisulfite sequencing PCR
BGS-forward
5′-GGTAGGGTTGATTTAGAGTTAG-3′
301
58 °C
BGS-Reverse
5′-CTTCAATACTCCATAAATACACC-3′
Methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS)
The procedure for sodium bisulfite modification of DNA was performed as described [18, 19]. Bisulfite-modified DNA was amplified using MSP, with primer sets specifically detecting methylated or unmethylated alleles. PCR products were separated on agarose gels. MSP analyses were performed in duplicate. To analyze the methylation status of the targeted region in the CYB5R2 promoter, bisulfite-treated DNA was amplified with a BGS PCR primer set. Amplified PCR products were subcloned and transformed into JM109 competent cells. Several isolated plasmid clones from each cell line or biopsy were sequenced using the BigDye terminator-cycle sequencing kit 3.0 (Applied Biosystems, USA) on an ABI 3100 sequencer.
5-Aza-2′-deoxycytidine (5-aza-dC) treatment
Four NPC cell lines (CNE1, CNE2, HONE1 and C666-1) were seeded into six-well plates at 2 × 105 cells/well. The next day, cells were treated with the DNA methyltransferase inhibitor 5-aza-dC (Sigma) at 10 μM for 96 h, and medium with freshly added 5-aza-dC was replaced every 24 h. Total RNA was extracted for semi-quantitative RT-PCR as described.
Vector construction and transfection
The full-length coding sequence of CYB5R2 from Origene (USA) was subcloned into the pCMV-Tag3A vector (Stratagene, USA). The NPC cell line HONE1, which showed downregulated CYB5R2, was transfected with the pCMV-Tag3A-CYB5R2 plasmid or control pCMV-Tag3A using Lipofectamine 2000 (Invitrogen, USA). Stable clones were obtained by G418 selection (400 μg/ml) for 2 weeks and maintained in 200 μg/ml G418.
Colony formation assay
Aliquots of 1 × 105 HONE1 cells were transfected as described above. After 48 h, the cells were transferred to 60-mm cell culture dishes and selected in 400 μg/ml G418 for 2 weeks. Giemsa-stained colonies were photographed and counted using the Quantity One v4.4.0 software (Bio-Rad, USA). The experiment was performed in triplicate.
Cell proliferation assay
To determine the cell proliferation rate, stably transfected empty vector-HONE1 and CYB5R2-HONE1 cells were seeded into 96-well plates at 2 × 103 cells per well. Cell density at different time points was measured using the vital stain 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Solarbio) and the absorbance (OD490 nm) was measured in a microplate reader (iMark, Bio-Rad, USA). Cells were cultured for 5 days, and five wells from each group were chosen as replicates every 24 h.
Wound healing assay
Empty vector-HONE1 and CYB5R2-HONE1 cells (5×105 per well) were seeded in six-well plates and allowed to adhere for 24 h. Confluent monolayers of cells were scratched by a sterile 1 ml micropipette tip. Photographs were taken at 0 and 24 h at the same position of the wound and the regrowth of cells into the wound area was measured. The experiment was performed in triplicate.
In vivo tumor growth assay
Eight female 6-week-old Balb/c athymic nude mice (Experimental Animal Center of Guangxi Medical University, China) were used. The experimental protocol for tumor formation in nude mice was approved by the Ethical Review Committee of First Affiliated Hospital of Guangxi Medical University, and the committee's ethical guidelines for animal experimentation were followed. A total of 2×106 HONE1 cells, stably transfected with CYB5R2, were subcutaneously injected into the right flank of the nude mice. An equal amount of empty vector-HONE1 cells were injected into the left flank of the mice as a control. The growth of tumors was monitored every 2 days for 2 weeks after inoculation. Tumor volume (V) was calculated as V = (π/6)L × W × H, where L, W, and H represent tumor diameters in three mutually orthogonal planes. The tumor was removed and weighed on day 14.
Anzeige
Statistical analysis
Statistical analysis was performed using SPSS v16 (SPSS Inc., Chicago, IL, USA). Data are shown as mean ± SD. The association of promoter methylation status with clinical pathological features of NPC patients was analyzed by Pearson chi-square or Fisher's exact test. Paired t test was used to compare in vivo experiment groups. A P value <0.05 was considered statistically significant.
Results
Inactivation of CYB5R2 in NPC cell lines and primary tumors
To investigate the expression of CYB5R2 in NPC cell lines and NPC biopsies, semi-quantitative RT-PCR was performed. As demonstrated in Fig. 1a, CYB5R2 mRNA expression was undetectable in NPC cell lines CNE1, HONE1, and HNE1 while weak expression was detected in CNE2, TW03, and C666-1. As well, CYB5R2 expression was downregulated in the 20 NPC primary tumor biopsies but easily detected in all NNE samples (Fig. 1b).
Fig. 1
Expression of cytochrome b5 reductase 2 (CYB5R2) in NPC cell lines, NPC biopsies and NNE samples. a RT-PCR analysis of expression of CYB5R2 in NPC cell lines and NNEs. PC: positive control. GAPDH was the internal control. Water was the blank control. b Semi-quantitative RT-PCR of CYB5R2 expression in NNEs and primary NPC tumors. CYB5R2 expression was normalized to that of GAPDH
×
The CYB5R2 promoter is hypermethylated in NPC cell lines and primary tumors
Having established that CYB5R2 was downregulated in NPC cell lines and primary biopsies, we further investigated the promoter methylation status of CYB5R2. MSP results showed that the CYB5R2 promoter was hypermethylated in the six NPC cell lines (CNE1, CNE2, TW03, HONE1, HNE1 and C666-1; see Fig. 2a) and in 84 % (42/50) of NPC primary tumors but in none of the 12 NNE samples (Fig. 2b). Unmethylated amplicons were detected in some primary NPC biopsy samples but were most likely due to contaminating non-malignant cells such as stromal cells in a fraction of the tissue samples.
Fig. 2
Analysis of the methylation status of the CYB5R2 promoter region in NPC cell lines, NPC primary tumors and NNE samples. a MSP analysis in NPC cell lines and NNEs. M methylated alleles, U unmethylated alleles. In vitro methylated DNA was used as a methylation-positive control and DNA from normal lymphocytes was the positive control for unmethylated alleles. The blank control was water. b MSP analysis in NPC biopsies and NNE, representative data is shown. c Methylation status of the 39 CpG sites of the CYB5R2 promoter in two NPC cell lines (TW03 and CNE2), two NPC biopsies (NPC15 and 27) and one NNE biopsy (NNE7). Five clones were randomly selected and sequenced for each sample. Different size filled sectors of the circles represent the fraction of methylated CpG. MSP primer locations are indicated by frames. d Restoration of CYB5R2 expression by treatment with 5-aza-dC in NPC cell lines. One NNE sample and CYB5R2 expression plasmid DNA were used as positive controls
×
CpG sites in the CYB5R2 promoter are heavily methylated in NPC cell lines and NPC biopsies
To reveal the detailed methylation status of individual CpG sites, we analyzed the DNA sequence of the promoter region −389 to −89 bp of CYB5R2 using BGS in two NPC cell lines (TW03 and CNE2), two NPC biopsies (NPC15 and NPC27) and one normal biopsy (NNE7) (Fig. 2c). All 39 CpG sites were heavily methylated in TW03 and CNE2, in agreement with our finding of downregulated CYB5R2 expression in these NPC cell lines. As well, the two NPC biopsies tested showed intense methylation. The presence of some unmethylated CYB5R2 promoter sequences among the clones originating from the two NPC cell lines TW03 and CNE2 may be due to heterogeneity in the original cell lines. The NNE sample was nearly completely free of methylation. The BGS data also demonstrate that our bisulfite conversion of genomic DNA was complete which supports the reliability of our MSP results.
Anzeige
Transcription of CYB5R2 could be restored by 5-aza-dC treatment
The expression of CYB5R2, which was silenced or downregulated in the NPC cell lines CNE1, CNE2, HONE1 and C666-1, could be restored after 96 h 5-aza-dC treatment (Fig. 2d). This provides support for our hypothesis that CYB5R2 downregulation in NPC is an epigenetic event and not due to genetic rearrangement or mutation of the gene or its promoter.
Clinico-pathological significance of CYB5R2 promoter hypermethylation in NPC
Clinical characters of the 50 NPC patients were collected, and we found a significant association of CYB5R2 promoter hypermethylation with the clinico-pathological variable lymph node metastasis (P < 0.05), however, there was no significant correlation to age, sex, cancer stage, or pathological subtypes (Table 2).
Table 2
Association of CYB5R2 promoter methylation status and clinicopathological characteristics of NPC patients
No. of patients
Promoter methylation status
P value
Methylated
Unmethylated
Age (years)
NS
< 60
37
30
7
≥ 60
13
10
3
Sex
NS
Male
35
28
7
Female
15
11
4
Cancer stagea
NS
I
4
3
1
II
15
12
3
III
17
12
5
IV
14
12
2
Histological subtype
NS
Keratinizing squamous cell carcinoma
7
6
1
Non-keratinizing carcinoma
43
35
8
Lymph node metastasis
P < 0.05
Presence
33
33
0
Absence
17
10
7
Data are number of patients
NS not significant
aAccording to the International Union Against Cancer (UICC)
Reexpression of CYB5R2 in NPC cells suppresses colony formation and cell proliferation and inhibits cell migration
To assess whether CYB5R2 might have properties of a TSG in NPC, we examined the effect of CYB5R2 on clonogenicity and cell proliferation in HONE1 cells. The number of colonies was lower for CYB5R2-HONE1 than empty vector-HONE1 cells (P < 0.05) (Fig. 3a). As well, CYB5R2-HONE1 cells grew significantly slower than HONE1 parental and empty vector-HONE1 cells (Fig. 3c). To measure the effect of CYB5R2 reexpression on cell mobility, we used a wound healing assay. Cell movement into the scratched area was slower for CYB5R2-HONE1 than for empty vector-HONE1 cells, which suggests that ectopic expression of CYB5R2 effects a reduction in the motility of NPC cells (Fig. 3b).
Fig. 3
Ectopic expression of CYB5R2 inhibits colony formation, migration and proliferation of NPC cells. a Colony formation ability of CYB5R2-transfected and empty vector-transfected HONE1cells. Colony numbers in the bar graph represent the mean ± SD of three independent experiments. b Migration of CYB5R2-transfected and empty vector-transfected HONE1cells examined by wound healing assay. c Growth curves of CYB5R2-transfected, empty vector-transfected HONE1cells and parental cells. Data are mean ± SD (n = 5). *P < 0.05
×
Inactivation of CYB5R2 is critical for tumorigenesis in vivo
We further assessed the tumor suppressing capacity of CYB5R2 in vivo. Empty vector-HONE1 and CYB5R2-HONE1 cells were injected into the left and right flanks, respectively, of Balb/c athymic nude mice and tumor growth was monitored with 2-day intervals. Mice injected in the flanks with control cells formed larger tumors within 14 days, whereas mice injected in the flanks with CYB5R2-HONE1 showed greatly reduced tumor growth (P < 0.05) (Fig. 4). Thus, ectopic expression of CYB5R2 reverses the tumor growth which is associated with its epigenetic downregulation in the HONE1 cells.
Fig. 4
CYB5R2 reexpression reduces tumorigenicity of NPC cells in nude mice. a Growth curves of tumors in nude mice. The mean volume of tumors from CYB5R2-HONE1 and empty vector-HONE1 cells was evaluated every 2 days after inoculation. Data are mean ± SD (n = 8). b Representative tumors were removed from the nude mice at day 14 after transplantation. c Mean ± SD weight of tumors (n = 8). *P < 0.05
×
Anzeige
Discussion
NPC has been proposed to be the result of a multistep process involving environmental carcinogens, genetic factors and latent EBV infection. Among these etiologic factors, EBV is a well-recognized causative factor not only for NPC, but for a number of human malignancies [20]. However, although EBV infects and persists in about 90 % of the human population, NPC develops in only a minority of EBV-infected individuals, which suggests that other risk factors may be involved in disease development. Environmental factors such as lifestyle and occupational exposure to chemical carcinogens and tumor promoters have been suggested as cofactors [3]. Examples of the most relevant environmental exposures are Cantonese-style salted fish, fermented fish sauce and other preserved foods [3, 8]. These foods contain large amounts of N-nitrosodimethylamine (NDMA), N-nitrosopyrrolidene (NPYR) and N-nitrosopiperidine (NPIP), which may contribute to the carcinogenic development in NPC [21]. Occupational exposure to formaldehyde and wood dust are risk factors as well [22‐24]. Moreover, cigarette smoke has been consistently found as a moderate risk factor for NPC [7, 25]. Polycyclic aromatic hydrocarbons, nitrosamines and aromatic amines are known carcinogens in cigarette smoke [26, 27]. These aromatic amines can either be activated to carcinogenic aromatic hydroxylamine derivatives in the cytochrome P450 pathway or detoxified by N-acetylation in the cytochrome B5 reductase (CYB5R) pathway [16]. The nitrenium or nitroso derivatives produced in the cytochrome P450 activation pathway generate mutagenic DNA adducts while the end products of the CYB5R mediated detoxification pathway are cleared as N-acetylated, water soluble products. Alterations of genes that encode phase I and phase II xenobiotic biotransformation enzymes [9], involved in metabolic activation or detoxification of potentially carcinogenic substances, have been demonstrated as risk factors for NPC [10‐13].
In the present study, we demonstrate that the mRNA expression of a xenobiotic-metabolizing enzyme, CYB5R2, was downregulated in NPC cell lines and primary tumors. The CYB5R2 promoter was aberrantly methylated in all six NPC cell lines (100 %) and in 42 of 50 (84 %) primary NPC tumors, but not in any of the 12 normal controls. Bisulphite genomic sequencing demonstrated that all 39 CpG sites in the tested CYB5R2 promoter were heavily methylated in the NPC cell lines CNE2 and TW03, where CYB5R2 expression is downregulated. A high degree of methylation was also observed in primary NPC tumors. CYB5R2 expression could be restored in four NPC cell lines after treatment with the demethylating agent 5-aza-dC. These results indicate that CYB5R2 was transcriptional inactivation in NPC, and the major mechanism could be a high degree of methylation in its promoter region, which might contribute to the tumorigenesis of NPC.
The expression of CYB5R2 has been evaluated in several human malignancies. Consistent with our findings, microarray analysis revealed that CYB5R2 is downregulated in lobular and ductal invasive breast cancer biopsies and functions as a regulator of cell proliferation, differentiation and transformation [28]. However, these findings are inconsistent with observations in acute B lymphoblastic leukemia, in which CYB5R2 is upregulated [29]. Thus, epigenetic inactivation of CYB5R2 might be tissue-specific events.
Hypermethylated DNA can serve as a biomarker for cancer detection because of its high specificity in distinguishing cancers from normal tissues. We found that the CYB5R2 promoter region was subject to methylation in all of our six NPC cell lines and 84 % of NPC biopsies. Therefore, CYB5R2 promoter hypermethylation is a frequent event in NPC and not just a phenomenon associated with in vitro cell culture. In addition, epigenetic silencing of CYB5R2 was a tumor-specific event and could be detected in both early- and advanced-stage NPC biopsies, which suggests that CYB5R2 promoter hypermethylation might contribute both to the initiation and progression of NPC. CYB5R2 methylation could serve as a potential biomarker for early diagnosis of NPC. However, due to the lack of patients' follow-up study, we suffered from the limitation that no correlation between the expression of CYB5R2 and the survival rate of NPC patients was verified.
Lymph node metastasis is one of the most significant features of NPC [30]. It is strongly correlated to reduced survival rate and increased risk of tumor recurrence. Identification of biomarkers for lymph node metastasis in NPC would be helpful in designing optimized and individualized therapeutic regimens for NPC. Our finding that CYB5R2 promoter methylation is associated with lymph node metastasis in NPC, suggests that CYB5R2 promoter methylation may serve as a diagnostic indicator of lymph node metastasis, which would have great value for the clinical evaluation of NPC cases.
We show that ectopic expression of CYB5R2 significantly inhibited cell proliferation, colony formation and migration of NPC cells in vitro. Moreover, exogenous expression of CYB5R2 inhibits tumorigenicity of NPC cells in vivo in a mouse model system. This evidence strongly implies that CYB5R2 is a putative TSG and plays a role in nasopharyngeal carcinogenesis. To our knowledge, this is the first report of a xenobiotic-metabolizing enzyme functioning as a tumor suppressor in NPC.
In summary, our data demonstrate for the first time that CYB5R2 is epigenetically inactivated by promoter hypermethylation in a human cancer, NPC. Our experimental data provide support for CYB5R2 as a novel and important candidate TSG in NPC. We revealed a frequent and tumor-specific hypermethylation of the CYB5R2 promoter in NPC and a significant association of CYB5R2 promoter hypermethylation with lymph node metastasis, which suggests that the epigenetic state of the CYB5R2 promoter may serve as a diagnostic biomarker and present a possible therapeutic target for NPC.
Acknowledgements
We thank Professor Gosta Winberg (Karolinska Institutet, Sweden), for critical comments and suggestions. This study was supported by grants from the National Basic Research Program of China (2011CB504304 and 2012CB526607), Program for New Century Excellent Talents in University (NCET-12-0654), National Natural Scientific Foundation of China (81060167) and Guangxi Natural Science Foundation (2013GXNSFGA019002). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Conflicts of interest
None
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma
verfasst von
Xue Xiao Weilin Zhao Fangyun Tian Xiaoying Zhou Jinyan Zhang Tingting Huang Bo Hou Chunping Du Shumin Wang Yingxi Mo Nana Yu Shiping Zhou Jinping You Zhe Zhang Guangwu Huang Xianjie Zeng
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
